Abstract
Combined chemoradiation therapy is currently the standard practice for locally advanced rectal cancer (LARC) with uninvolved mesorectal fascia (MRF). The CONVERT study compares neoadjuvant chemotherapy with CapeOx alone to standard chemoradiotherapy (CRT) with Capecitabine for these patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
